RecruitingBreast Cancer
Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
Eligible age
18+ yrs
Accepts
All genders
Locations
3 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This trial is to investigate if in patients with clinically node positive breast cancer undergoing upfront surgery, treatment with TAS and ART is superior to ALND in terms of arm-related Quality of Life (QoL) and occurrence of lymphedema two years after randomization.
Sponsor: University Hospital, Basel, Switzerland
You may qualify if…
- ✓ Written informed consent according to ICH/GCP regulations prior to any trial specific procedures.
- ✓ Patients ≥ 18 years of age.
- ✓ Node-positive breast cancer (histologically or cytologically proven both in primary tumor and in lymph node) American Joint Committee on Cancer/ International Union Against Cancer (AJCC/UICC) stage II-III (all molecular subtypes allowed).
- ✓ Node-positivity detected by imaging and non-palpable (iN+) and confirmed by pathology.
- ✓ Node-positivity palpable (cN1-3) and confirmed by pathology.
- ✓ Occult breast cancer is allowed, if biopsy-proven axillary lymphatic metastasis is present.
- ✓ Eligible for primary ALND or SLN procedure and either:
- ✓ Newly diagnosed.
You may not qualify if…
- ✕ Stage IV breast cancer.
- ✕ Clinical N3c breast cancer without axillary disease (clinical N3a and clinical N3b are allowed).
- ✕ Clinical N2b breast cancer (clinical N2a is allowed).
- ✕ Contralateral breast cancer within 3 years.
- ✕ Prior axillary surgery (except prior sentinel node procedure in case of in-breast recurrence).
- ✕ Prior regional radiotherapy.
- ✕ Neoadjuvant treatment with the exception of bridging therapy given for less than 3 months.
- ✕ History of hematologic or primary solid tumor malignancy, unless in remission for at least 3 years from pre-registration with the exception of adequately treated cervical carcinoma in situ or localized non-melanoma skin cancer.
Where it's recruiting
Source: ClinicalTrials.gov · NCT07140172 · last updated 2026-10-14